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Giovanni Camussi *
Stem Cell Laboratory, Department of Medical Sciences, University of Torino, Torino, Italy
Extra-cellular vesicles (EVs) are bilayer membrane structures enriched with proteins,
nucleic acids, and other active molecules and have been implicated in many physiological
and pathological processes over the past decade. Recently, evidence suggests EVs to
play a more dichotomic role in the regulation of the immune system, whereby an immune
response may be enhanced or supressed by EVs depending on their cell of origin and its
functional state. EVs derived from antigen (Ag)-presenting cells for instance, have been
involved in both innate and acquired (or adaptive) immune responses, as Ag carriers or
presenters, or as vehicles for delivering active signaling molecules. On the other hand,
tumor and stem cell derived EVs have been identified to exert an inhibitory effect on
immune responses by carrying immuno-modulatory effectors, such as transcriptional
factors, non-coding RNA (Species), and cytokines. In addition, stem cell-derived EVs
have also been reported to impair dendritic cell maturation and to regulate the activation,
differentiation, and proliferation of B cells. They have been shown to control natural
killer cell activity and to suppress the innate immune response (IIR). Studies reporting
the role of EVs on T lymphocyte modulation are controversial. Discrepancy in literature
may be due to stem cell culture conditions, methods of EV purification, EV molecular
content, and functional state of both parental and target cells. However, mesenchymal
stem cell-derived EVs were shown to play a more suppressive role by shifting T cells
from an activated to a T regulatory phenotype. In this review, we will discuss how
stem cell-derived EVs may contribute toward the modulation of the immune response.
Collectively, stem cell-derived EVs mainly exhibit an inhibitory effect on the immune
system.
Keywords: extracellular vesicles, exosomes, stem cells, immune system, immuno-modulation
INTRODUCTION
Extra-cellular vesicles (EVs) are bilayer membranal structures released by cells as a means of
transferring their content to and from other cells, now acknowledged as a novel mechanism
of intercellular communication. These vesicles comprise of both membrane and cytoplasmic
components including: proteins, nucleic acids, and other active molecules and can be sub classified
according to size, biogenesis, and composition into exosomes or microvesicles (also defined as
shedding vesicles; Théry et al., 2009; EL Andaloussi et al., 2013; Yáñez-Mó et al., 2015; see Figure 1).
The term “microvesicle” generally refers to both vesicles released by healthy cells as well as
pre-apoptotic vesicles. They are commonly heterogeneous in size ranging from 50 to 1000 nm in
diameter depending on the state of the cell during release by either direct shedding or budding
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from the plasma membrane (Figure 1). Exosomes, on the
other hand, are generated through an invagination process of
the endosomal membrane of multi-vesicular bodies (MVBs)
found within the cells forming vesicles. This is followed by
fusion of the MVBs with the plasma membrane leading to
exocytosis and release of exosomes which are homogenous in
size with a diameter ranging from 40 to 200 nm (Figure 1;
Yáñez-Mó et al., 2015). Since exosomes and microvesicles share
several molecular and functional characteristics and are released
concomitantly by the same cell types, the term EVs will be
used to collectively indicate the two subtypes throughout this
review.
EVs carry a plethora of molecules that influence their
mode of action. These include a variety of receptors, adhesion
molecules, proteins involved in cell trafficking, and/or intra-
cellular signal transduction, cytoskeletal proteins, cytoplasmic
enzymes, cytokines, chemokines, as well as cell-specific antigens
(Ags). Moreover, they are also enriched with a range of
nucleic acids, including mRNA, long non-coding RNAs,
microRNAs (miRNA), and even extra-chromosomal DNA
(Robbins and Morelli, 2014; Yáñez-Mó et al., 2015). The
content carried however may vary depending on the type
of cell and the state of activation. Once released, these EVs
may interact with neighboring cells or diffuse through and
circulate in the bloodstream or other organic fluids such
as: breast milk, semen, saliva, urine, and sputum. Their
state of ubiquity makes them important effectors of cell-
to-cell communication, which may occur in a paracrine,
autocrine, exocrine, and or endocrine manner (Yáñez-Mó et al.,
2015).
Virtually all cell types have the ability to release EVs including
cells of the immune system such as: macrophages, antigen
presenting cells (APCs), dendritic cells (DCs), B and T cells
(both CD4+ T helper and CD8+ cytotoxic T lymphocytes),
natural killer cells (NKs), as well as cells complementing
the immune system such as platelets, mast cells, fibroblasts,
epithelial cells, and stem cells. Recently, there has been enough
growing evidence to suggest that EVs play an essential role in
immuno-modulation (Robbins and Morelli, 2014), influencing
both the activation and suppression of the immune response.
Furthermore, a role of EVs has also been implicated in
inflammation, autoimmune, infectious, and cancer diseases
(Yáñez-Mó et al., 2015). This review will however focus on
the interactions of stem-cell derived EVs with the immune
system.
Abbreviations: EVs, Extra-cellular vesicles; Ag(s), Antigen(s); miRNA,
MicroRNA; APCs, Antigen presenting cells; DCs, Dendritic cells; NKs, Natural
killer cells; IIR, Innate immune response; AIR, Acquired immune response;
TGF-β, Transforming Growth factor-β; CTLs, Cytotoxic T-lymphocytes; RA,
Rheumatoid arthritis; SC(s), Stem cell(s); ESCs, Embryonic stem cells; MSCs,
Mesenchymal stem/stromal cells; iPS, Induced pluripotent stem cells; IFN-γ,
Interferon-γ; TNF-α, Tumor Necrosis Factor-α; HGF, Hepatocyte Growth
Factor; NO, Nitric oxide; IDO, Indoleamine 2,3-dioxygenase; HLA-G, Human
Leukocyte Antigen-G; PG, Prostaglandin; IL, Interleukin; CXCR4/CXCR5/CCR7,
Chemokine Receptor Type 4/5–7; PBMCs, Peripheral Blood Mononuclear Cells;
GAD65, Glutamic Acid Decarboxylase 65; NKG2D, Natural-Killer Group-2
Member-D receptor; MHC, Major Histocompatibility Complex; siRNA, Small
interfering RNA; BM, Bone Marrow; ASCs, Adipose Stem Cells.
REGULATION OF IMMUNE RESPONSE BY
EVs
The immune system can be divided into two branches: the
innate immune response (IIR)—an evolutionary conserved
system common to all multicellular organisms, and the acquired
or adaptive immune response (AIR)—an exclusive feature
developed in vertebrates (Sirisinha, 2014).
Within the IIR system, EVs act as paracrine messengers,
allowing the propagation of pro-inflammatory signals
(Mastronardi et al., 2011; Wang et al., 2011; Prakash et al., 2012;
Cloutier et al., 2013). However, they have also been reported to
contribute as negative regulators of the inflammatory response
primarily by carrying molecules such as Transforming Growth
factor-β (TGF-β), and other immuno-suppressive mediators
(Gasser and Schifferli, 2004). The role of EVs in the regulation
of IIR is complex and has not yet been fully elucidated. Many
studies so far have investigated the composition and function of
EVs from innate immune cells cultured in-vitro. For instance,
macrophages treated in vitro with EVs isolated from cells
infected with Mycobacterium tuberculosis released cytokines
and chemokines that contributed toward the activation of the
immune response (Walters et al., 2013). On the other hand,
macrophages infected with the Leishmania parasite secreted
EVs enriched with the Leishmania surface protein gp63, which
down-regulated the inflammatory response, favoring parasite
invasion (Hassani and Olivier, 2013).
Whereas, IIR is a non-specific first line of defense against
microbial pathogens and other tissue injuries, AIR is a specific
response induced after Ag recognition by adaptive immune cells
followed by activation and clonal expansion of immune cells
carrying the recognized Ag-specific receptors (Schenten and
Medzhitov, 2011; Zhang et al., 2014). In this setting, EVs may
act not only as Ag carriers (since they may transfer bacterial,
viral, and tumoral components to APCs; O’Neill and Quah, 2008;
Walker et al., 2009; Testa et al., 2010), but also as modulators of
direct and indirect Ag presentation. Furthermore, this property
of EVs to carry Ags from parental cells can allow them to act
as reporters of foreign agents in the organism both for the
host immune system as well as from a diagnostic point of view
(Yáñez-Mó et al., 2015). For example, tumor-derived EVs carry
tumor-Ags, which can be taken up and processed by DCs and
then cross-presented to tumor-specific cytotoxic T-lymphocytes
(CTLs; Wolfers et al., 2001; Andre et al., 2002). This has been
demonstrated for EVs isolated from ascites of tumoral patients
as well as other tumoral cell lines (Wolfers et al., 2001; Andre
et al., 2002; Morelli et al., 2004). This hypothesis is supported by
the fact that vaccination of mice with tumor peptide-pulsed DC-
derived EVs induces a potent CD8+ T cell-mediated anti-tumoral
effect (Wolfers et al., 2001). On the basis of these findings, it
can be speculated that tumor-derived EVs carry tumor-specific
Ags and that they could be used to stimulate or inhibit the
immune anti-tumoral surveillance (Robbins and Morelli, 2014).
In this regard, ongoing studies are exploring their potential role
in the field of anti-tumor vaccination, as reviewed by Kunigelis
et al. (Kunigelis and Graner, 2015). Furthermore, APC-derived
EVs can also act as “Ag-presenting vesicles” for in vitro T-cell
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FIGURE 1 | Biogenesis of EVs and their immuno-modulatory effects. EVs, Extracellular Vesicles; Ag, Antigen; IL, Interleukin; Ab, Antibodies.
clones (Théry et al., 2002; Muntasell et al., 2007; Nolte-’t Hoen
et al., 2009), however this activity appears to be 10–20 times less
efficient to that of corresponding APCs probably due to: the small
size, vesicle diffusion, and limited number of MHCmolecules per
vesicle (Zitvogel et al., 1998; Vincent-Schneider et al., 2002; Qazi
et al., 2009).
Many recent studies on EVs have focused on the dichotomic
effects they have on the immune system (see Figure 1). There
are studies that have reported that EVs are able to promote
the immune response by carrying foreign Ags (Bhatnagar
and Schorey, 2007; Robbins and Morelli, 2014) as well as
inflammatory cytokines (Pizzirani, 2007; Zuccato et al., 2007)
and therefore also play a role in mediating chronic inflammatory
and autoimmune diseases. For instance, EVs derived from
synovial fluid of patients with rheumatoid arthritis (RA) have
higher levels of TNF-alpha compared to healthy controls
(Zhang et al., 2006). Furthermore, these EVs are able to delay
activated T-cell mediated cell death, thereby contributing to
the pathogenesis of RA (Zhang et al., 2006). Similarly, EVs
isolated from broncho-alveolar fluid of patients with sarcoidosis
display pro-inflammatory activity (Qazi et al., 2010). On the other
hand, EVs can also have the opposite effect, mediating immuno-
suppression. For instance, EVs derived from stimulated T cells
are found to be enriched with major histocompatibility complex
(MHC) molecules, T-cell receptors (TCR), APO2 ligand, Fas
ligand (FasL), and Natural-Killer Group-2 Member-D receptor
(NKG2D), which have the ability to not only inhibit Natural
killer cell (NK) cytotoxicity but also promote apoptosis of T-cells
and down-regulation of Ag processing by APCs (Monleón et al.,
2001; Busch et al., 2008; Xie et al., 2010; Hedlund et al., 2011).
Although, the function of EVs to either promote or suppress the
immune response depends on the type of cell they are released
from, including tumors, those derived from stem cells have
mainly demonstrated suppressive properties.
INVOLVEMENT OF STEM CELL-DERIVED
EVs IN IMMUNO-MODULATION
Advances in stem cell (SC) technology have opened interesting
perspectives in the field of translational medicine in terms of
regenerative and therapeutic strategies. Classically, stem cells
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TABLE 1 | Potential EV-derived effectors reported to play a role in immuno-modulation.
Effector Type Cell source Function References
Nanog Transcriptional factor ESCs Tumoral cells immune-escape Ratajczak et al., 2006b; Yáñez-Mó et al., 2015
Oct-4 Transcriptional factor ESCs Innate immune suppression Ratajczak et al., 2006b; Lee et al., 2012
HoxB4 Transcriptional factor ESCs Through WNT signaling affects DCs maturation and
T-cells proliferation, differentiation, and activation
Ratajczak et al., 2006b; Staal et al., 2008
Rex-1 Transcriptional factor ESCs Through PIP3 signaling stimulate innate immune
response and neutrophils activity
Weiner, 2002; Ratajczak et al., 2006b
Oct4 mRNA ESCs Innate immune suppression Katsman et al., 2012; Noh et al., 2012
Sox2 mRNA ESCs Initiate innate response against microbial infection
through neutrophils activation
Katsman et al., 2012; Xia et al., 2015
CD81 CD9 Membrane protein iPS Immune system cell adhesion, motility, activation,
and signal transduction
Levy et al., 1998; Hu et al., 2015
miR-21 miRNA iPS Inhibiting effect on granulopoiesis O’Connell et al., 2010; Wang et al., 2015b
TGF-β1 Cytokine MSCs Maintain tolerance through regulation of lymphocyte
proliferation and survival
Bruno et al., 2015
IL-6 Cytokine MSCs Interfere effect in DCs maturation Djouad et al., 2007
IL-10 Cytokine MSCs Suppress T lymphocytes proliferation Hwu et al., 2000
PGE-2 Prostaglandin MSCs Inhibit NKs activity and proliferation Aggarwal and Pittenger, 2005; Spaggiari et al., 2006
Suppress T lymphocytes proliferation
Interfere effect in DCs maturation
IDO Enzyme MSCs Inhibit NKs activity and proliferation Hwu et al., 2000
miR-155 miR-146 miRNA MSCs miR-155 promotes, while miR-146 reduce,
inflammatory reaction in mice
Di Trapani et al., 2016
HGF Growth factor MSCs Suppress T lymphocytes proliferation Di Nicola et al., 2002
ESCs, Embryonic Stem Cells; iPS, induced Pluripotent Stem Cells; MSCs, Mesenchymal Stromal/Stem Cells; IL, Interleukin; TGF, Transforming Growth Factor; PG, Prostaglandin; IDO,
Indoleamine 2,3-dioxygenase; HGF, Hepatocyte Growth Factor. In Italic, EVs-carried effector for which it has been directly demonstrated the immuno-modulatory effect.
can be classified into two main categories: embryonic stem cells
(ESCs) and adult (or tissue) SCs (Nawaz et al., 2016).
ESCs are pluripotent cells that have the ability to differentiate
into cells from any of the three embryonic germ layers:
mesoderm, ectoderm, and endoderm. Furthermore, they can
self-renew and proliferate indefinitely. As they are derived from
embryos at 5–6 days post conception; their use is fairly limited
due to ethical concerns on availability as well as for the risk
of forming teratomas (Alvarez et al., 2012; Nawaz et al., 2016).
Another sub type of SCs is the recently described induced
pluripotent stem cells (iPS) which are adult cells that are
engineered by manipulating the expression of certain genes to
induce re-programming of the cell back to a pluripotent state
(Takahashi and Yamanaka, 2006; Alvarez et al., 2012).
Adult stem cells are cells located in fetal and adult tissues;
they have limited differentiation capabilities compared to ESCs,
and are involved in the maintenance of cell turnover and tissue
repair. Nomenclature of adult SCs depends mainly on the source
of origin for example: SCs from the bone marrow are known
as hematopoietic stem cells and mesenchymal stem/stromal cells
(MSCs), and SCs from the nervous system as neural stem cells
etc. (Alvarez et al., 2012).
The biological effect of SCs partly depends on a paracrine
mechanism whereby, secreted factors including: growth factors,
miRNAs, and EVs, influence stem cell regeneration and
differentiation as well as mediate crosstalk to and from local and
distant tissues (Lai et al., 2010; Zanotti et al., 2013; Wang et al.,
2015a). SC-secreted factors have been reported to exhibit several
properties such as: anti-apoptotic and angiogenic effects, cell-
mobilization, maintenance of homeostasis as well as immune-
modulation amongst others (Burdon et al., 2011; Tsuji and
Kitamura, 2015). Furthermore, apart from secreted factors, stem
cell-derived EVs have also been reported to mimic the effect
of SCs after internalization by target cells (injured cells in
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the context of regeneration), mainly through receptor–ligand
mediated interactions and/or direct fusion, leading to horizontal
transfer of proteins and nucleic acids (including mRNA and non-
coding RNA; Ratajczak et al., 2006a; Valadi et al., 2007; Camussi
et al., 2010).
Many authors in the recent years have focused their research
in studying the role of EVs (from various cellular origins)
in immuno-modulation, however, very little studies have been
reported that address the role of SC-derived EVs in the immune
system particularly on IRR and AIR. Table 1 shows references
of studies that have reported potential effectors identified within
EVs that exhibit immuno-modulatory properties. The reason for
such limited studies in the literature may partly be due to the fact
that the role of SC-EVs as potential immune-modulatory effect is
still novel (Nawaz et al., 2016) and partly due to the reporting of
controversial results. Nevertheless, in order to elucidate the novel
role(s) of SC-EVs on the immune system as well as to clarify
the reported controversies in the results, further studies in this
subject are only warranted.
Ratajczak et al. first reported that EVs released by ESCs might
modulate the phenotype of target cells, supporting self-renewal
of hematopoietic progenitors and multi-potency by transfer of
growth factors and messenger-RNA (mRNA) (Ratajczak et al.,
2006b). Subsequent studies confirmed this horizontal transfer of
genetic material in other contexts, such as endothelial progenitor
induced angiogenesis and modulation of bone-marrow cell
phenotype by EVs released by injured tissues (Deregibus et al.,
2007; Aliotta et al., 2010). Furthermore, ESC-derived EVs may
not only contribute to cell-fate determination but also to tissue
repair and various other physio-pathological processes, but their
role as immuno-modulators has not yet been fully elucidated.
Nonetheless, ESC-derived EVs have been reported to carry
transcriptional factors and mRNAs such as: Nanog, octamer-
binding transcription factor 4 (Oct-4), HoxB4, Rex-1, Oct4, and
Sox2 that have immuno-modulatory properties (see Table 1). For
instance, Nanog has been described in tumor cell immuno-escape
(Ratajczak et al., 2006b; Noh et al., 2012), Oct-4 in the inhibition
of IIR (Ratajczak et al., 2006b; Lee et al., 2012), and HoxB4 in
impairment of DC maturation, and T-cell proliferation through
a WNT-mediated mechanism (Ratajczak et al., 2006b; Staal et al.,
2008). Whereas, Rex-1 and Sox2 have been shown to stimulate
IIR (Weiner, 2002; Ratajczak et al., 2006b; Katsman et al., 2012;
Xia et al., 2015). However, a direct role of ESC-derived EVs on the
immune system through the above described effectors has yet to
be reported. Similar to ESCs, little is known about the functions
of iPS-derived EVs on the immune system. The available studies
show that membrane proteins, such as CD81 and CD9, and miR-
21 are carried by iPS-derived EVs and that these effectors may
affect the immune response by regulating: cell adhesion, motility,
activation and signal transduction (see Table 1; Levy et al., 1998;
O’Connell et al., 2010; Hu et al., 2015; Wang et al., 2015b).
Amongst adult SCs, MSCs are certainly the most studied
type (Pittenger et al., 1999; Bruno et al., 2015). In addition to
regenerative effects in animal models (Syed and Evans, 2013),
there is increasing evidence describing their role in both IIR
and AIR modulation (MacDonald et al., 2011; Dalal et al.,
2012). For instance, MSCs are able to not only inhibit NK
proliferation and activity but also suppress T-/B-cell proliferation
and DC maturation (Keating, 2012; Bruno et al., 2015).
Furthermore, high levels of IFN-γ and TNF-α influence MSCs
to develop immuno-suppressive properties toward IIR (affecting
neutrophils, monocytes, and NKs) and AIR (T- and B-cells)
(Corcione et al., 2006; Krampera et al., 2006; Spaggiari et al., 2006;
Uccelli et al., 2008; Le Blanc andMougiakakos, 2012). MSCs have
also been reported to have a marked immuno-regulatory effect
against autoimmune disorders and promising results have been
observed in clinical trials on patients with Crohn’ s disease and
graft-vs.-host disease (Pittenger, 2009; Caplan and Correa, 2011).
It is still widely debated as to whether the immuno-
modulatory action of MSCs relies on direct cell-to-cell
interaction or on the paracrine action of soluble mediators
released by these cells. Either one or both mechanisms are a
possibility. Both, in vivo and in vitro studies have demonstrated
that MSCs exhibit an immuno-suppressive role by suppressing
T lymphocyte proliferation (Krampera et al., 2003; Aggarwal
and Pittenger, 2005). A possible explanation for this role
could be the presence of proteins and factors such as: TGF-β,
hepatocyte growth factor (HGF), nitric oxide (NO), indoleamine
2,3-dioxygenase (IDO), human leukocyte antigen G (HLA-G),
prostaglandin E2 (PGE-2), Inter Leukin (IL)-6, and IL-10 (Hwu
et al., 2000; Aggarwal and Pittenger, 2005; Spaggiari et al., 2006;
Djouad et al., 2007; Sato et al., 2007; English et al., 2009; Caplan
and Correa, 2011) that are expressed highly by MSCs. For
instance, It has been suggested, that IDO, PGE-2, and TGF-β1
are involved not only in the inhibition of NK cells but also in the
inhibition of T-cell proliferation and activation (Aggarwal and
Pittenger, 2005; Spaggiari et al., 2006). Furthermore, IL-6 has also
been attributed to interfere with DC maturation (English et al.,
2009). Finally, with a mechanism not completely known, MSCs
have been reported to inhibit B-cells proliferation through the
down-regulation of chemokine receptor CXCR4, CXCR5, and
chemokine receptor type 7 (CCR7) (Corcione et al., 2006). The
immuno-modulatory effects of MSCs can therefore be speculated
to be achieved either through the release of the above mentioned
factors and proteins directly into the extracellular milieu as
soluble molecules, or they may be packaged into EVs together
with nucleic acids and other post-transcriptional modulators
which could influence the inflammatory response when released
(Robbins and Morelli, 2014).
The ability of MSC-derived EVs to mimic the effect of the cell
of origin has been studied on various different effector cells of
the immune system (Blazquez et al., 2014; Conforti et al., 2014;
Favaro et al., 2014, 2016; Zhang, 2014; Amarnath et al., 2015; Del
Fattore et al., 2015; Gouveia de Andrade et al., 2015; Di Trapani
et al., 2016; see Table 2).
The inhibitory effect of MSC-derived EVs on the activation of
cells of the immune system has been demonstrated by various
studies. For example, Conforti et al. reported an inhibitory
activity of MSCs and MSC-derived EVs on B-cell proliferation,
which was further confirmed by a study conducted by Di
Trapani et al. (Conforti et al., 2014). Del Fattore et al. also
demonstrated that MSC-derived EVs not only increased the ratio
between regulatory T-cells and effector T-cells, but also increased
the release of the immunosuppressive cytokine IL-10, however,
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TABLE 2 | The effect of stem cell derived EVs on the immune system.
Cell source Target cell EVs effect References
Human ASCs T-lymphocytes Down-regulation of T-cells proliferation Blazquez et al., 2014
Human BM-MSCs T-lymphocytes Immuno-suppression through A2A receptor Amarnath et al., 2015
Human BM-MSCs T-lymphocytes T regulatory cells increase Del Fattore et al., 2015
Increased release of IL-10
Human BM-MSCs B-lymphocytes Down-regulation of B-cells proliferation Conforti et al., 2014
Down-regulation of B-cells differentiation
Inhibition of IgM, IgG and IgA production
Human ESC-derived MSCs Activated murine splenocytes Splenocytes proliferation down-regulation Zhang, 2014
Switch to an M2-macrophage like phenotype
Increase of T regulatory cells in vivo
Human BM-MSCs PBMCs from type 1 diabetes patient Down-regulation of Th1 mediated response Favaro et al., 2014
T regulatory cells increase
Th17 cells decrease
Human BM-MSCs Monocyte-derived DCs Induction of regulatory DCs phenotype with inhibition
of T-cell dependent immune response
Favaro et al., 2016
Human BM-MSCs PBMCs, MSCs, NKs, B, and T-cells Inhibition of NKs and B-cell proliferation Di Trapani et al., 2016
Increase of MSCs immunosuppressive properties
BM, Bone Marrow; MSCs, Mesenchymal Stromal/Stem Cells; ESCs, Embryonic Stem Cells; PBMCs, Peripheral Blood Mononuclear Cells; ASCs, Adipose Stem Cells; DCs, Dendritic
cells.
IDO an established mediator of MSC immunosuppressive
effects was not affected (Del Fattore et al., 2015). A possible
way by which MSC-EVs exhibit these immunomodulatory
properties could be through an adenosine A2A receptormediated
mechanism (Amarnath et al., 2015). In addition, the extracellular
environment could also play a role, for instance it has been
reported that an inflammatory environment (mimicked in
culture by the presence of IFN-γ and TNF-α) may not only
alter the release but also influence the biological activity of
MSC-derived EVs toward a more immunosuppressive role. In
fact MSC-derived EVs may polarize monocytes toward M2-like
phenotype, which in turn induces CD4+ T cell to differentiate
into regulatory T cells (Zhang, 2014). A study by Blazquez et al.
also reported that EVs derived from human adipose stem cells
had an inhibitory effect not only on the differentiation and
activation of T cells but also on the release of IFN-γ (Blazquez
et al., 2014). In addition it has been shown that IFN-α or -γ
transferred by EVs are also able to activate immunological
molecular pathways into target cells (Li, 2013; Cossetti, 2014).
A study carried out by Favaro et al. looking at the effect of
MSC-EVs on peripheral blood mononuclear cells (PBMCs) from
type 1 diabetic patients revealed some interesting results. They
showed that, MSC-derived EVs inhibited IFN-γ production in
PBMCs stimulated by the islet Ag glutamic acid decarboxylase 65
(GAD65) and significantly increased the production of immune-
modulatory mediators such as PGE-2, TGF-β, IL-10, and IL-6.
In addition, there was a reduction in the number of Th17 cells
as reflected by the reduction in IL17 secretion and an increase
in regulatory T-cells in the same setting, suggesting that T-cells
switched to an anti-inflammatory phenotype in the presence of
EVs (Favaro et al., 2014). Furthermore, in a later study they
reported that DCs conditioned with MSC-derived EVs acquired
an immature phenotype with increased IL-10 secretion, which
contributed toward inhibition of inflammatory T-cell response
against islet Ags (Di Nicola et al., 2002; Favaro et al., 2014, 2016).
Although some very interesting studies have been reported in
the literature explaining the immuno-modulatory functions of
EVs on T-cell proliferation, there are some that are controversial.
For instance, Conforti et al. and Gouveia de Andrade et al.
both reported that the immuno-modulatory effects of EVs on
T-cells are absent or significantly lower compared to MSCs
(Conforti et al., 2014; Gouveia de Andrade et al., 2015).
However, the apparent discrepancy observed in the different
studies may depend on different methodological approaches
and the activation state of the EV cell of origin. Recently
Krampera’s group attempted to standardize the method for
studying the immunomodulatory effects of MSC-derived EVs,
comparing unfractionated PBMCs with purified T, B, and NK
cells (Di Trapani et al., 2016). In this study, they demonstrated a
direct correlation between the degree of EV-mediated immuno-
suppression and EV uptake by immune effector cells. In the case
of PBMCs, most of the EVs were internalized by monocytes
rather than by B and T cells. Furthermore, MSC-derived EVs
did not significantly inhibit T-cell proliferation, whereas down-
regulated the proliferation of NK and B-cells. These effects were
enhanced by MSC-priming with inflammatory cytokines (Di
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Trapani et al., 2016). On investigating they observed that priming
with MSCs increased the level of immunomodulatory miRNAs,
such as miRNA-155 andmiRNA-146 and that EVs obtained from
primed MSCs potentiated the immunosuppressive properties of
resting MSCs on T-cells with a mechanism that was independent
to a direct EV inhibition of T-cell proliferation (Di Trapani et al.,
2016).
Taken together these studies suggest that EVs derived from
MSCs are less effective than the cells themselves, as the latter may
act either by direct cell-to-cell interaction as well as by releasing
several active soluble factors. Moreover, the biological effect of
EVs may vary depending extracellular micro-environment. A
pro-inflammatory environment for instance may modify the
composition of EVs and the consequent biological activities as
well as the activation state of immune effector cells targeted by
these EVs.
POTENTIAL THERAPEUTIC
APPLICATIONS AND CONCLUDING
REMARKS
The ability of EVs to either enhance or suppress the immune
response may be exploited in immuno-therapy. This dualistic
effects of EVs makes them very flexible and lucrative, but, it
also increases the risk of unpredictable adverse effects (Zhang
et al., 2014). Several studies have reported how EV-dependent
immuno-modulation can be correlated to the source type and the
state of the cell of origin (activation and maturation degree). For
example: APC and DC derived EVs can regulate Ag-specific and
non-specific immune responses, both positively and negatively
(Robbins and Morelli, 2014). The immunogenicity depends on
the expression levels of MHC-class I and II, as well as co-
stimulatory molecules such as CD80 and CD86 (Thomson and
Robbins, 2008).
Although tumor-derived EVs seem to be mainly involved
in immune-escape mechanisms, it has been demonstrated
that APCs pulsed with EVs derived from tumor cells may
cross-present Ags and stimulate the activation of an Ag-specific
CTL-mediated anti-tumoral response (Escudier, 2005; Morse
et al., 2005). This was also confirmed in a clinical trial conducted
by Bu et al. on malignant gliomas (Bu et al., 2011). However,
other clinical trials have also revealed the low immunogenicity
of tumor-derived EVs, which represents the main limitation for
this therapeutic strategy (Kunigelis and Graner, 2015).
The horizontal transfer of nucleic acid by EVs can be
equally exploited in several therapeutic approaches (Robbins
and Morelli, 2014). For example engineering EVs with miRNA
or small interfering RNA (siRNA), capable of promoting or
silencing the expression of particular transcripts, could be
adopted in the future as therapeutic strategies.
Immune-cell-based and stem cell based therapies currently
present several risks and complications as well as technical
problems such: culture-induced senescence, immune-mediated
rejection, genetic instability, loss of functional properties, and
malignant transformation that need to be solved to make them
successful (Nawaz et al., 2016). EVs which mimic in part the
effect of the stem cells from which they are derived may
represent a novel cell-free solution, which could overcome some
of the limitations mentioned above linked to cell based therapies
(Zhang, 2014). Giebel et al. in a case report demonstrated the
feasibility of an in vivo EV approach for the therapy of refractory
graft vs. host disease (Kordelas et al., 2014). The results of this
study suggested a beneficial effect of MSC-derived EVs as anti-
inflammatory and immune-modulatory mediators in the context
of a severe inflammatory and immune disease. Nevertheless, in
order to develop an effective and successful immuno-therapy
based on stem cell derived EVs warrants not only further
studies to clarify the mechanism of action of EVs, but also the
standardization of protocols for isolation and characterization
(Witwer et al., 2013).
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